Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01664000 · ClinicalTrials.gov registry record · Phase 1
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Cellceutix Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01664000 is a Phase 1 study that has completed, run by Cellceutix Corporation. The registered enrollment target is 48 participants.
The verdict
NCT01664000, a Phase 1 study, has completed, sponsored by Cellceutix Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
In the laboratory, Kevetrin activates p53, a tumor suppressor protein that has an important role in protecting the body. p53 functions by activating proteins that repair DNA and kill cells that have genetic mutations such as in cancers. Research experiments showed that when cancer cells were treated with Kevetrin, it activated p53 which induced p21, a protein that inhibits cancer cell growth. p53 also induced PUMA (p53 up-regulated modulator of apoptosis), a protein that causes tumor cell death. Because of these activities, slowing cancer cell growth and causing cancer cell death, Kevetrin may help to treat tumors.
Interventions
- DRUG thioureidobutyronitrile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01664000
The ClinicalTrials.gov registry entry for NCT01664000 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellceutix Corporation, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which thioureidobutyronitrile is the first listed.
NCT01664000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01664000 about?
NCT01664000 is a clinical study titled "A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors". In the laboratory, Kevetrin activates p53, a tumor suppressor protein that has an important role in protecting the body. p53 functions by activating proteins that repair DNA and kill cells that have genetic mutations such as in cancers. Research experiments showed that when cancer cells were treated...
What is the current status of trial NCT01664000?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2012-10. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01664000?
The interventions under investigation include: thioureidobutyronitrile (DRUG).
Who is sponsoring clinical trial NCT01664000?
This trial is sponsored by Cellceutix Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.